{"denoms":[{"counts":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"25"}],"units":"Participants"}],"groups":[{"description":"Patients are stratified between high risk and low risk disease status.\n\nHigh risk patients receive 1 cycle of R-CODOX-M chemotherapy IV followed by R-IVAC chemotherapy over 30 minutes(Regimen B); regimens A and B are then repeated.\n\nRegimen A: Cyclophosphamide (800 mg/m2 IV over 1 hour)+ vincristine (1.5 mg/m2 IV PUSH)+ doxorubicin (40 mg/m2 IV)+ high-dose methotrexate (2,700 mg/m2 IV over 23 hours)+ rituximab (500 mg/m2 IV)(R-CODOX-M) regimen","id":"BG000","title":"High Risk - Treated With Alternating R-CODOX-M/R-IVAC Cycles"},{"description":"Patients are stratified between high risk and low risk disease status. Low risk patients receive 3 cycles of rituximab (500 mg/m2) R-CODOX-M chemotherapy IV over 2-4 hours with intrathecal chemotherapy (Regimen A).\n\nRegimen A: Cyclophosphamide (800 mg/m2 IV over 1 hour)+ vincristine (1.5 mg/m2 IV PUSH)+ doxorubicin (40 mg/m2 IV)+ high-dose methotrexate (2,700 mg/m2 IV over 23 hours)+ rituximab (500 mg/m2 IV)(R-CODOX-M) regimen\n\nRegimen B: Rituximab (500 mg/m2 IV once)+ Ifosfamide (1500 mg/m2 IV daily over 3 hours)+ Etoposide (60 mg/m2 IV daily over 1 hour), and Cytarabine (2 grams/m2 IV over 3 hours for 4 doses) 4 doses)","id":"BG001","title":"Low Risk - Treatment With 3 Cycles of R-CODOX-M"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"21"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"22"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"22"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"25"}]}],"title":"United States"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Region of Enrollment","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"}],"title":"Positive"},{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"21"}],"title":"Negative"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Human Immunodeficiency Virus (HIV) Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"8"}],"title":"Within Normal Range"},{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"17"}],"title":"Elevated"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Lactate dehydrogenase (LDH) Level","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"9"}],"title":"0"},{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"10"}],"title":"1"},{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"6"}],"title":"2"}]}],"description":"Eastern Cooperative Oncology Group Performance Status (ECOG PS) determines the ability of patients being able to tolerate therapies in serious illness. Scale is as follows:\n\n0 = Asymptomatic, normal activity\n\n1. = Symptomatic but completely ambulatory\n2. = Symptomatic, less than 50% of time in bed but not bedbound\n3. = In bed more than 50% of the time\n4. = 100% bedridden\n5. = death","paramType":"COUNT_OF_PARTICIPANTS","title":"Eastern Cooperative Oncology Group Performance Status (ECOG PS)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"8"}],"title":"Yes"},{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"17"}],"title":"No"}]}],"description":"Bulky disease is defined as disease in which there is a tumor mass more than 10 cm in its greatest diameter","paramType":"COUNT_OF_PARTICIPANTS","title":"Bulky disease","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"4"}],"title":"Stage I"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"}],"title":"Stage II"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"}],"title":"Stage III"},{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"15"}],"title":"Stage IV"}]}],"description":"Classification for Hodgkin Lymphoma ranging from I-IV with IV being worse disease with liver or bone marrow, lungs or cerebrospinal fluid involvement.","paramType":"COUNT_OF_PARTICIPANTS","title":"Ann Arbor Stage","unitOfMeasure":"Participants"}]}